Mattson, Anita Elaine
University of Massachusetts Medical Center
UMass Medical Center
HIV Protease Inhibitors (PIs) have become one of the most effective anti-viral drugs on the market. Darunavir (DRV), the most potent FDA-approved PI, has been essential in the fight against HIV/AIDS. However, the ability of the HIV protease to mutate and grow resistance has become a global concern. To address this issue, two new series of PIs were designed using the substrate envelope hypothesis. UMass 1-10 and the mono-/di-hydroxyl series compounds are derived from the DRV backbone, with modifications made on the P1' and P2' sites. The compounds were kinetically tested against resistant mutants and crystal structures were solved. Pico-molar potencies were observed for all compounds. These results can be used to design new PIs with increased efficacy against a wide range of mutants.
Worcester Polytechnic Institute
Major Qualifying Project
All authors have granted to WPI a nonexclusive royalty-free license to distribute copies of the work, subject to other agreements. Copyright is held by the author or authors, with all rights reserved, unless otherwise noted.
Chemistry and Biochemistry